{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:45:49Z","timestamp":1789400749855,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-020-01049-3","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T01:04:20Z","timestamp":1611277460000},"page":"1001-1010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors"],"prefix":"10.1007","volume":"39","author":[{"given":"Quincy Siu-chung","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Bouganim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zaknoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Stille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill D.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hua","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lithio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Batist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","volume":"13","author":"E Willems","year":"2018","unstructured":"Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN, Rogister B (2018) The functional diversity of Aurora kinases: a comprehensive review. Cell Div 13:7. https:\/\/doi.org\/10.1186\/s13008-018-0040-6","journal-title":"Cell Div"},{"key":"1049_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.critrevonc.2009.03.009","volume":"73","author":"JJ Kitzen","year":"2010","unstructured":"Kitzen JJ, de Jonge MJ, Verweij J (2010) Aurora kinase inhibitors. Crit Rev Oncol Hematol 73:99\u2013110. https:\/\/doi.org\/10.1016\/j.critrevonc.2009.03.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"1049_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrm1245","volume":"4","author":"M Carmena","year":"2003","unstructured":"Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842\u2013854. https:\/\/doi.org\/10.1038\/nrm1245","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fonc.2015.00278","volume":"5","author":"V Bavetsias","year":"2015","unstructured":"Bavetsias V, Linardopoulos S (2015) Aurora kinase inhibitors: current status and outlook. Front Oncol 5:278. https:\/\/doi.org\/10.3389\/fonc.2015.00278","journal-title":"Front Oncol"},{"key":"1049_CR5","first-page":"1420","volume":"9","author":"TM Gritsko","year":"2003","unstructured":"Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ (2003) Activation and overexpression of centrosome kinase BTAK\/Aurora-A in human ovarian cancer. Clin Cancer Res 9:1420\u20131426","journal-title":"Clin Cancer Res"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2007-07-099325","volume":"111","author":"XF Huang","year":"2008","unstructured":"Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q (2008) Aurora kinase inhibitory VX-680 increases Bax\/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111:2854\u20132865. https:\/\/doi.org\/10.1182\/blood-2007-07-099325","journal-title":"Blood"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/blood-2008-06-164889","volume":"113","author":"T Ochi","year":"2009","unstructured":"Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, Kuzushima K, Yasukawa M (2009) Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 113:66\u201374. https:\/\/doi.org\/10.1182\/blood-2008-06-164889","journal-title":"Blood"},{"key":"1049_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fonc.2015.00295","volume":"5","author":"AB D\u2019Assoro","year":"2016","unstructured":"D\u2019Assoro AB, Haddad T, Galanis E (2016) Aurora-A kinase as a promising therapeutic target in cancer. Front Oncol 5:295. https:\/\/doi.org\/10.3389\/fonc.2015.00295","journal-title":"Front Oncol"},{"key":"1049_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1541-7786.MCR-12-0707","volume":"11","author":"T Dobson","year":"2013","unstructured":"Dobson T, Chen J, Krushel LA (2013) Dysregulating IRES-dependent translation contributes to overexpression of oncogenic Aurora A kinase. Mol Cancer Res 11:887\u2013900. https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0707","journal-title":"Mol Cancer Res"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1541-7786.MCR-06-0208","volume":"5","author":"J Fu","year":"2007","unstructured":"Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5:1\u201310. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0208","journal-title":"Mol Cancer Res"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"23937","DOI":"10.18632\/oncotarget.14893","volume":"8","author":"A Tang","year":"2017","unstructured":"Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J (2017) Aurora kinases: novel therapy targets in cancers. Oncotarget 8:23937\u201323954. https:\/\/doi.org\/10.18632\/oncotarget.14893","journal-title":"Oncotarget"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/1535-7163.MCT-18-0529","volume":"18","author":"J Du","year":"2019","unstructured":"Du J, Yan L, Torres R et al (2019) Aurora A selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells and shows potent preclinical antitumor efficacy. Mol Cancer Ther 18:2207\u20132219. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0529","journal-title":"Mol Cancer Ther"},{"key":"1049_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13543784.2018.1417382","volume":"27","author":"S Liewer","year":"2018","unstructured":"Liewer S, Huddleston A (2018) Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors. Expert Opin Investig Drugs 27:105\u2013112. https:\/\/doi.org\/10.1080\/13543784.2018.1417382","journal-title":"Expert Opin Investig Drugs"},{"key":"1049_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10637-012-9825-7","volume":"31","author":"GK Schwartz","year":"2013","unstructured":"Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI (2013) Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 31:370\u2013380. https:\/\/doi.org\/10.1007\/s10637-012-9825-7","journal-title":"Invest New Drugs"},{"key":"1049_CR15","doi-asserted-by":"publisher","unstructured":"Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Lomberk GA, Haddad T, Degnim A, Lange C, Ingle JN, Galanis E, D\u2019Assoro AB (2014) Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ER\u03b1 expression in initially ER\u03b1+ breast cancer cells. PLoS One 9:e96995. https:\/\/doi.org\/10.1371\/journal.pone.0096995","DOI":"10.1371\/journal.pone.0096995"},{"key":"1049_CR16","doi-asserted-by":"publisher","unstructured":"Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51\u201362. https:\/\/doi.org\/10.1016\/s1535-6108(02)00235-0","DOI":"10.1016\/s1535-6108(02)00235-0"},{"key":"1049_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bbrc.2011.01.001","volume":"405","author":"CC Wu","year":"2011","unstructured":"Wu CC, Yu CT, Chang GC, Lai JM, Hsu SL (2011) Aurora-A promotes gefitinib resistance via a NF-kappaB signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun 405:168\u2013172. https:\/\/doi.org\/10.1016\/j.bbrc.2011.01.001","journal-title":"Biochem Biophys Res Commun"},{"key":"1049_CR18","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/ijc.22154","volume":"119","author":"H Yang","year":"2006","unstructured":"Yang H, He L, Kruk P, Nicosia SV, Cheng JQ (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119:2304\u20132312. https:\/\/doi.org\/10.1002\/ijc.22154","journal-title":"Int J Cancer"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"12016","DOI":"10.1200\/JCO.2018.36.15_suppl.12016","volume":"36","author":"SA Wander","year":"2018","unstructured":"Wander SA, Cohen O, Johnson GN, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway LA, Winer EP, Lin NU, Wagle N (2018) Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i). J Clin Oncol 36:12016. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.12016","journal-title":"J Clin Oncol"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cort\u00e9s J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V (2016) Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76:2301\u20132313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0728","journal-title":"Cancer Res"},{"key":"1049_CR21","unstructured":"National Comprehensive Cancer Network (2018) NCCN clinical guidelines version 1.2018. Breast Cancer"},{"key":"1049_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","volume":"9","author":"X Gong","year":"2019","unstructured":"Gong X, Du J, Parsons SH et al (2019) Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov 9:248\u2013263. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0469","journal-title":"Cancer Discov"},{"key":"1049_CR23","unstructured":"Tate SC, Hui Y-H, Barda D, Henry J, Du J. Dose fractionation study design and PK\/PD model analysis to establish the quantitative pharmacology of selective Aurora A kinase inhibition by Compound X and LY3295668. Paper presented at the 27th Meeting of the Population Approach Group Europe, Montreux, Switzerland, 29 May\u20131 June, 2018"},{"key":"1049_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","volume":"16","author":"B Melichar","year":"2015","unstructured":"Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C (2015) Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol 16:395\u2013405. https:\/\/doi.org\/10.1016\/S1470-2045(15)70051-3","journal-title":"Lancet Oncol"},{"key":"1049_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00280-010-1377-y","volume":"67","author":"EC Dees","year":"2011","unstructured":"Dees EC, Infante JR, Cohen RB, O\u2019Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H (2011) Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 67:945\u2013954. https:\/\/doi.org\/10.1007\/s00280-010-1377-y","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01049-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01049-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01049-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:05:26Z","timestamp":1678511126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01049-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01049-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This trial was conducted in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonisation and with the principles of the Declaration of Helsinki. All trial protocols and documentation were approved by the institutional review board or independent ethics committee at each investigational site: McGill University Health Centre Research Ethics Board (Project number: MP-37-2017-2682); Health Research Ethics Board of Alberta-Cancer Committee (Ethics ID: HREBA.CC-17-0102_REN3). Written informed consent was obtained from all patients before participation in any study-related activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"QC, NB, and GB declare no potential conflict of interest related to this submitted work. CF was the CEO of AurKa Pharma Inc. while the clinical research described in this article was conducted. SZ has acted as a consultant for Daiichi Sankyo and Mirati. JRS, JDK, EY, YHH, AdlP, AL, and PSS are employees of Eli Lilly and Company.\u00a0","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}